Caron Alyce Jacobson, M.D.
This page shows the publications co-authored by Caron Jacobson and Jeremy Abramson.
HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART. Adv Hematol. 2012; 2012:507257.
Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. J Clin Oncol. 2020 09 20; 38(27):3095-3106.
Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. Blood. 2021 03 11; 137(10):1353-1364.
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2019 Aug; 6(8):e419-e428.
Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. Blood Adv. 2019 04 09; 3(7):1167-1174.
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016 07 14; 128(2):195-203.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.